Research programme: calcium channel stabilisers - ARMGO PharmaAlternative Names: Ryanodine receptor calcium-release channel (RyR) modulators - ARMGO Pharma; Rycals; S 107
Latest Information Update: 06 Sep 2012
At a glance
- Originator ARMGO Pharma
- Class Small molecules
- Mechanism of Action Ryanodine receptor calcium release channel modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cognition disorders; Musculoskeletal disorders